Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06890377

Enrollment

Registered

2025-03-24

Start date

2024-09-14

Completion date

2026-03-31

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P)

Keywords

Multiple System Atrophy, PETCT, α-synuclein

Brief summary

The aim of this study was to apply the targeted α-synuclein PET study technique to investigate the pathological load and spatial distribution characteristics of α-syn in MSA patients, and to assess its value as a biomarker for diagnostic typing, disease severity, and prognosis in MSA.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

35 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Age\> 35 years old, gender is not limited; * Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria; * all patients had been ruled out of polyQ disease by genetic testing; * Voluntarily participate in this study and sign the informed consent form.

Exclusion criteria

* pregnancy or breastfeeding; * contraindications to MRI examination or inability to cooperate in completing neuroimaging examination; * previous history of other neurological disorders or presence of other organic intracranial lesions on neuroimaging that cannot be interpreted by MSA, such as epilepsy, trauma, tumors, or high-grade cerebral white matter degeneration (Fazekas grade 2 and above); * History of alcohol or drug abuse

Design outcomes

Primary

Measure	Time frame
Standard uptake value ratio(SUVR)	From enrollment to the end of treatment at 4 weeks

Secondary

Measure	Time frame	Description
UMSARS	From enrollment to the end of treatment at 4 weeks	Unified Multiple System Atrophy Rating Scale
H-Y stage	From enrollment to the end of treatment at 4 weeks	—
MoCA score	From enrollment to the end of treatment at 4 weeks	Montreal Cognitive Assessment
Wexner score	From enrollment to the end of treatment at 4 weeks	Wexner Continence Grading Scale
Frontal Assessment Battery	From enrollment to the end of treatment at 4 weeks	—
SCOPA-AUT	From enrollment to the end of treatment at 4 weeks	Parkinson's Disease Autonomic Symptoms Scale

Countries

China

Contacts

Primary ContactHe RQ 何

hrq1234562001@163.COM0086-18622148869

Outcome results